uploads/2018/12/PFE-income-1.png

Pfizer’s Stock Performance and Earnings Trends

By

Updated

Stock performance

On December 17, Pfizer’s stock price closed at $43.11, which is an ~1.58% decline from its close of $43.80 on December 14. Pfizer’s stock price grew from $36.22 at the close of the market on December 29, 2017, to $43.11 at the close of the market on December 17, 2018, which reflects ~19% YTD (year-to-date) growth.

On December 17, the company’s stock price closed at $43.11, which represents ~30% growth from its 52-week low of $33.20 on February 9. Pfizer hit its 52-week high of $46.47 on December 4.

Article continues below advertisement

Earnings trends

Pfizer’s net income in the first nine months of 2018 amounted to $11.5 billion—compared to $9.0 billion during the same period in 2017, which reflects ~28% YoY (year-over-year) growth. Wall Street analysts expect Pfizer to generate a net income of $13.0 billion in fiscal 2018.

Pfizer’s net income in the third quarter was $4.1 billion—compared to $2.8 billion during the same period in 2017, which reflects ~45% YoY growth. Wall Street analysts expect Pfizer to generate a net income of $2.3 billion in the fourth quarter.

Pfizer reported a diluted EPS of $1.92 in the first nine months of 2018—compared to $1.49 during the same period in 2017, which reflects ~29% YoY growth. In the third quarter, the company reported a diluted EPS of $0.69—compared to $0.47 in the third quarter of 2017, which reflects ~46% YoY growth.

Wall Street analysts expect Pfizer to report a diluted EPS of $0.34 and $2.30, respectively, in the fourth quarter and fiscal 2018.

In the third quarter, Pfizer’s peers in the biopharmaceutical market, Merck (MRK), Johnson & Johnson (JNJ), and Novartis (NVS) reported a net income of $2.0 billion, $3.9 billion, and  $1.6 billion, respectively.

Pfizer and Johnson & Johnson’s earnings growth could boost the iShares Russell 1000 Value ETF’s (IWD) share prices. Pfizer and Johnson & Johnson account for ~2.04% and ~2.31% of IWD’s total portfolio holdings, respectively.

Advertisement

More From Market Realist